SpringBio
spring生物科技公司成立于2001年由一組科學家取得了早期的成功與他們的線SP克隆兔單克隆抗體用于臨床**組化。這一勢頭很快被誰收購了該公司在2007年它的抗體開發能力的Ventana醫療系統發現。本塔納醫療系統是此后不久由羅氏公司收購。
DISCOVERY Protocols
Spring Bioscience is creating working protocols for immunohistochemistry using our antibodies. In addition to the protocol recommendation in the datasheets of each antibody, here you will find protocols to some of our antibodies using the DISCOVERY XT ?.
|
Root Catalog Number
|
Product Name
|
|
E128
|
CD34 (Endothelial Cell Marker)
|
|
E1345
|
AKT-1/PKB (phospho S473)
|
|
E1381
|
GLUT-1
|
|
E1650
|
CEA/CD66e
|
|
E1736
|
CD44 Std
|
|
E1737
|
CD44 Std
|
|
E1754
|
CD34 (Endothelial Cell Marker)
|
|
E1868
|
CD163
|
|
E266
|
Dystrophin
|
|
E266
|
Dystrophin
|
|
E297
|
CEA/CD66e
|
|
E341
|
Claudin-1
|
|
E341
|
Claudin-1
|
|
M306
|
Ki-67 (SP6)
|
|
M306
|
Ki-67 (SP6)
|
|
M307
|
CD3 (SP7)
|
|
M307
|
CD3 (SP7)
|
|
M320
|
Vimentin (SP20)
|
|
M336
|
Syntaxin 1A (SP36)
|
|
M336
|
Syntaxin 1A (SP36)
|
|
M337
|
CD44 Std (SP37)
|
|
M338
|
CD31 (SP38)
|
|
M338
|
CD31 (SP38)
|
|
M343
|
Caveolin-1 (SP43)
|
|
M343
|
Caveolin-1 (SP43)
|
|
M347
|
BAX (SP47)
|
|
M349
|
Stathmin (SP49)
|
|
M349
|
Stathmin (SP49)
|
|
M376
|
SOX-2 (SP76)
|
|
M376
|
SOX-2 (SP76)
|
|
M381
|
Calpain (SP81)
|
|
M381
|
Calpain (SP81)
|
|
M396
|
CD163 (SP96)
|
|
M398
|
CD278/ICOS (SP98)
|
|
M403
|
Nestin (SP103)
|
|
M405
|
J-chain (SP105)
|
|
M405
|
J-chain (SP105)
|
|
M408
|
IKAROS (SP108)
|
|
M415
|
F4/80 (SP115)
|
|
M415
|
F4/80 (SP115)
|
|
M422
|
SLIT2 (SP122)
|
|
M422
|
SLIT2 (SP122)
|
|
M518
|
PTEN (SP218)
|
|
M442
|
PD-L1/CD274 (SP142)
|
今天spring作為**的羅氏公司的使命是提供伴隨診斷的抗體中心的重要角色。
Spring Bioscience是一家專注于組織病理學和**組化的生物技術公司，公司總部位于美國加利福尼亞普萊斯頓。該公司有大量應用于IHC的兔單克隆抗體，同時也是將這些抗體引入市場的公司之一。所有SP克隆抗體都是Spring Bioscience設計生產的，SP克隆抗體憑借其高親和性、靈敏度及特異性一直是同類**組化產品中*好的，多年以來Spring Bioscience的SP克隆抗體在實驗室獲得黃金標準的美譽。
Our Product Lines
Antibodies
Spring Bioscience offers a list of Rabbit Monoclonal (SP Clones), Rabbit Polyclonal and Mouse Monoclonal primary antibodies. These antibodies are developed specifically for use in immunohistochemistry (IHC).
View ?
Detection & Ancillaries
Spring Bioscience offers a complete line of detection systems and reagents optimized for use in immunohostiochemistry and are designed to meet the complex needs of research laboratories.
View ?
Recombinant Proteins
Spring Bioscience offers a list of proteins expressed in E. coli. Depending on the protein, these can be either full length or partial sequence and are fused at the N-terminus wit GST/His-tag.
View ?
New Products
Spring Bioscience continuously innovates and releases new products throughout the year. We strive to increase our product offering while maintaining the high quality expected by our customers.
View ?
Spring Bioscience是專給國際知名品牌代工的全球性抗體公司之一，它的一抗有三種規格：0.1ml(濃縮型)，1ml(濃縮型)，7ml(即用型)，其中0.1ml抗體大部分價格在1700元以下。進口的質量，比其他進口抗體更具優勢的價格及放心的售后服務，Spring Bioscience抗體是您的*優選擇。
Spring Bioscience是雌**受體SP1克隆抗體（Cat#M3014）的研發者及磚利擁有者。
Spring Bioscience是一家專注于組織病理學和**組化的生物技術公司，它有大量IHC的兔單克隆抗體，同時也是將這些抗體引入市場的公司之一，所有SP克隆抗體都是Spring Bioscience設計生產的，SP克隆抗體憑借其高親和性、靈敏度及特異性一直是同類**組化產品中*好的，多年以來Spring Bioscience的SP克隆抗體在實驗室獲得黃金標準的美譽。
Spring Bioscience是專給全球諸多國際知名品牌代工的全球性公司之一，它的一抗有三種規格：0.1ml（濃縮型），1ml（濃縮型），7ml（型），其中0.1ml抗體大部分報價在1600元左右。進口的質量、比其他進口抗體更具優勢的價格及放心的售后服務， Spring抗體是您的不二之選。
spring bioscience絲氨酸/蘇氨酸蛋白激酶B-RAF（BRAF）是Raf家族的一員。 BRAF突變在良性和惡性腫瘤是常見的。 BRAF改變和突變誘導激活段的構象變化中BRAF V600E突變占絕大多數，導致組成型激酶活性的BRAF的和下游目標連續的磷酸化。已在黑色素瘤，甲狀腺**狀癌，多形性xanthoastrocytomas，朗格漢斯細胞組織細胞增生癥，卵巢交界性腫瘤，節細胞膠質瘤，結直腸癌，毛細胞型星形細胞瘤檢測到BRAF V600E突變。
PRODUCT DETAILS:
TechnologyMouse Monoclonal
Clone NameVE1
ApplicationIHC-P, WB
Species Reactivity
TestedHu
Predicted by homology
IsotypeMouse IgG2a
ImmunogenSynthetic peptide representing the BRAF V600E mutated amino acid sequence from amino acid 596 to 606 （GLATEKSRWSG）
Cellular LocalizationCytoplasm
Control TissueColon Carcinoma with BRAF V600E mutation
Regulatory RatingResearch Use Only （RUO）
Entrez673
Storage Requirement2-8°C
Target Molecular Weight95 kDa
FormulationRefer to Data Sheet
Catalog No. Volume Dilution
E19290 0.1ml 50
E19292 0.5ml 50
E19294 1.0ml 50
Our family of companies and history
Spring Bioscience Corporation (Spring) develops and manufactures rabbit monoclonal antibodies designed for use in IHC. Founded by scientists with a primary focus on IHC, Spring has developed a proprietary antibody menu of highly-sensitive “SP” clones that yield specificity and consistency for use in research. Spring was acquired by Ventana Medical Systems, Inc. (Ventana) in 2007 for its strong development capabilities, and shortly thereafter Ventana was acquired by Roche. Today Spring serves as the antibody center of excellence for all of Roche Tissue Diagnostics.
Our approach
Spring utilizes a diverse knowledge base for design input and keeps a strong focus on IHC throughout the entire antibody development process enabling us to deliver highly-defined and consistent SP clones. Spring’s pipeline focuses on novel targets requiring an exceptional understanding of biomarkers in order to deliver specificity. We collaborate with pharma partners and industry key opinion leaders for insights about specific biomarkers, and perform extensive research and evaluation to develop antibodies that bind appropriate biomarker sequences.
Commitment to quality
We are an ISO 9001:2015 certified company, with a focus on our commitment to product quality and continuous improvement.? Additionally, our reputation of collaboration with strategic partners, including those with affiliates such as Roche Diagnostics and Genentech, and with our research customers speaks to our dedication to advancing the industry as a whole.
Our technology
Spring uses proprietary recombinant technology to develop best-in-class rabbit monoclonal antibodies. Our technology ensures efficient scaling of manufacturing, lot to lot consistency, and reproducibility.
